Companies › Chia Tai Tianqing Pharmaceutical Group
34 active drug programs in 164 registered trials: 89 Phase 2, 36 Phase 1, 22 Phase 3, 17 Phase 4; Oncology, Infectious disease, Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Catequentinib Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 4 | Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma … | Dec 2026 |
| Adalimumab TNF-alpha inhibitor | TNF | Phase 4 | Adult Non-infectious Uveitis; Crohn's Disease; Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease; Takayasu Arteritis … | Feb 2028 |
| Penpulimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Advanced Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma; Advanced Pancreatic Cancer; Nasopharyngeal Neoplasms … | Dec 2026 |
| TQ05105 Tablets (Rovadicitinib Tablets) Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr | JAK1, JAK2, ROCK2 | Phase 3 | Graft-versus-host Disease; Chronic Graft Versus Host Disease; Myelofibrosis | Dec 2026 |
| TQB3454 tablets Selective IDH1 mutant enzyme inhibitor | IDH1 | Phase 3 | Biliary Carcinoma | Dec 2026 |
| TQB3616 capsule CDK2/4/6 inhibitor | CDK2, CDK4, CDK6 | Phase 3 | HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast Cancer | Dec 2026 |
| AL2846 Capsule Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET | MET, KIT, FLT4, RET | Phase 3 | Thyroid Cancer | Jan 2027 |
| TQB2102 for Injection HER2 antibody-drug conjugate | ERBB2 | Phase 3 | Breast Cancer | Jan 2027 |
| TQC3721 Suspension for Inhalation Phosphodiesterase 3/4 (PDE3/4) inhibitor | PDE3, PDE4 | Phase 3 | Chronic Obstructive Pulmonary Disease | Feb 2027 |
| TQB3473 Spleen tyrosine kinase (Syk) inhibitor | SYK | Phase 3 | Primary Immune Thrombocytopenia | Mar 2027 |
| Angiotensin Ii Type-1 angiotensin II receptor agonist | AGTR1 | Phase 3 | Vasodilatory Shock; Vasodilatory Hypotension During or After Cardiac Surgery; Cirrhosis, Liver; Septic Shock … | Jun 2027 |
| D-1553 Tablet KRAS G12C inhibitor | KRAS | Phase 3 | Non Small Cell Lung Cancer | Dec 2027 |
| TQ-B3234 capsules Selective MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Plexiform Neurofibroma | Dec 2027 |
| TQ-A3334 Viral replication inhibitor (HBV) | – | Phase 2 | Chronic Hepatitis B | Dec 2026 |
| TQB2450 injection humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1) | PDCD1LG1 | Phase 2 | Non Small Cell Lung Cancer | Dec 2026 |
| TQD3524 Polymyxin E2 methanesulfonate; hydrolyzed to polymyxin E2 and derivatives with bactericida | – | Phase 2 | Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | Jul 2027 |
| Benmelstobart injection PD-L1 inhibitor | PDCD1LG2 | Phase 2 | Alveolar Soft Part Sarcoma | Nov 2027 |
| TQB3702 tablets Tyrosine kinase inhibitor | – | Phase 2 | B-cell Lymphoma | Dec 2027 |
| TQB2825 injection CD20/CD3 bispecific antibody | CD20, CD3 | Phase 1 | Diffuse Large B Cell Lymphoma | Dec 2026 |
| TQB2930 for injection HER2 bispecific antibody | ERBB2 | Phase 1 | Metastatic Breast Cancer | Dec 2026 |
| TQB3122 Capsules PARP1 inhibitor | PARP1 | Phase 1 | Advanced Cancer | Dec 2026 |
| TQB3455 tablet IDH2 mutant enzyme inhibitor | IDH2 | Phase 1 | Acute Myeloid Leukemia (AML) | Dec 2026 |
| TQB3617 Capsules Bromodomain and Extra-Terminal (BET) inhibitor | BRD2, BRD3, BRD4, BRDT | Phase 1 | Myelofibrosis | Dec 2026 |
| TQF3250 capsules glucagon-like peptide-1 receptor agonist | GLP1R | Phase 1 | Hyperglycemia; Overweight/Obesity; Type 2 Diabetes Mellitus Combined With Overweight or Obesity | Dec 2026 |
| TQB6411 for Injection EGFR/c-Met dual-targeting antibody-drug conjugate | EGFR, MET | Phase 1 | Esophageal Cancer; Advanced Lung Cancer | Feb 2027 |
| TQB3107 Tablets selective target inhibitor that binds to target to induce apoptosis | – | Phase 1 | Advanced Cancers | Jun 2027 |
| LM-108 injection monoclonal antibody that selectively clears regulatory T cells (Tregs) infiltrating tumor | – | Phase 1 | Advanced Pancreatic Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2027 |
| TQB3019 capsule targeted protein degrader | – | Phase 1 | Advanced Malignant Cancer | Dec 2027 |
| TQB3142 for injection BCL-XL inhibitor | BCL2L1 | Phase 1 | Advanced Malignant Tumors | Dec 2027 |
| TQB3205 capsule targeted protein degrader | – | Phase 1 | Advanced Malignant Cancer | Dec 2027 |
| TQB3126 targeted protein degrader | – | Phase 1 | Breast Cancer | Aug 2029 |
| TQA3605 tablets Viral replication inhibitor | – | Phase 1 | Chronic Hepatitis b | – |
| TQB3002 EGFR tyrosine kinase inhibitor | EGFR | Phase 1 | Advanced Cancer | – |
| TQB3909 Protein inhibitor | – | Phase 1 | Myeloid Malignancy | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04300686 | Adalimumab | Phase 4 | Takayasu Arteritis | Immunology | May 2022 |
| NCT06482086 | Catequentinib | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | Oncology | Dec 2024 |
| NCT05365178 | TQB3616 capsule | Phase 3 | HR-positive, HER2-negative Breast Neoplasms | Oncology | Jul 2025 |
| NCT05807880 | Catequentinib | Phase 2 | Nasopharyngeal Neoplasms | Oncology | Jul 2025 |
| NCT05807880 | Penpulimab | Phase 2 | Nasopharyngeal Neoplasms | Oncology | Jul 2025 |
| NCT07011186 | TQB3909 | Phase 1 | Myeloid Malignancy | Oncology | Oct 2025 |
| NCT06662760 | TQB3002 | Phase 1 | Advanced Cancer | Oncology | Nov 2025 |
| NCT04743518 | Adalimumab | Phase 4 | Ulcerative Colitis | Immunology | Dec 2025 |
| NCT06150014 | TQA3605 tablets | Phase 1 | Chronic Hepatitis b | Infectious disease | Dec 2025 |
| NCT05685550 | Catequentinib | Phase 2 | Progression Free Survival(PFS) | Other | Dec 2025 |
| NCT06487585 | Angiotensin Ii | Phase 4 | Vasodilatory Hypotension During or After Cardiac Surgery | Cardiovascular | Jan 2026 |
| NCT03938701 | Adalimumab | Phase 2 | IBD | Immunology | Mar 2026 |
| NCT06886347 | Catequentinib | Phase 1 | Metastatic Nasopharyngeal Carcinoma | Oncology | Apr 2026 |
| NCT06939452 | Catequentinib | Phase 2 | Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Oncology | Jun 2026 |
| NCT05828953 | Catequentinib | Phase 2 | Interstitial Lung Diseases | Respiratory | Sep 2026 |
| NCT01426529 | Angiotensin Ii | Phase 1 | Hypertension | Cardiovascular | Oct 2026 |
| NCT05926700 | Catequentinib | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT06122831 | TQ05105 Tablets (Rovadicitinib Tablets) | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT07480824 | TQ05105 Tablets (Rovadicitinib Tablets) | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT07708272 | TQ05105 Tablets (Rovadicitinib Tablets) | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT07608666 | TQ05105 Tablets (Rovadicitinib Tablets) | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT04344158 | Catequentinib | Phase 3 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT04854668 | Catequentinib | Phase 3 | Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05862337 | Catequentinib | Phase 3 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT05913089 | Catequentinib | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06838910 | Catequentinib | Phase 2 | Thymic Carcinoma | Oncology | Dec 2026 |
| NCT05780567 | TQB3616 capsule | Phase 3 | Breast Cancer | Oncology | Dec 2026 |
| NCT06702618 | TQB3616 capsule | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06202261 | TQB3616 capsule | Phase 1 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT07269145 | TQB3122 Capsules | Phase 1 | Advanced Cancer | Oncology | Dec 2026 |
| NCT06122831 | TQB3617 Capsules | Phase 1 | Myelofibrosis | Oncology | Dec 2026 |
| NCT04344158 | Penpulimab | Phase 3 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
| NCT05862337 | Penpulimab | Phase 3 | Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT05576480 | Penpulimab | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT07327281 | TQF3250 capsules | Phase 1 | Hyperglycemia | Other | Dec 2026 |
| NCT06202261 | TQB2930 for injection | Phase 1 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT06829771 | TQB2825 injection | Phase 1 | Diffuse Large B Cell Lymphoma | Oncology | Dec 2026 |
| NCT06706310 | TQ-A3334 | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT05913089 | TQB2450 injection | Phase 2 | Non Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05987358 | TQB3454 tablets | Phase 3 | Biliary Carcinoma | Oncology | Dec 2026 |
| NCT06550713 | TQB3455 tablet | Phase 1 | Acute Myeloid Leukemia (AML) | Oncology | Dec 2026 |
| NCT04592744 | Angiotensin Ii | Phase 4 | Cirrhosis, Liver | Gastroenterology | Dec 2026 |
| NCT05260671 | Penpulimab | Phase 2 | Head and Neck Neoplasms | Oncology | Dec 2026 |
| NCT05400070 | Catequentinib | Phase 2 | Sintilimab | Oncology | Dec 2026 |
| NCT05220267 | Catequentinib | Phase 2 | Non Clear Cell Renal Carcinoma | Oncology | Dec 2026 |
| NCT06211790 | Catequentinib | Phase 2 | Kidney Cancer | Oncology | Dec 2026 |
| NCT06114225 | Penpulimab | Phase 2 | Osteosarcoma | Oncology | Dec 2026 |
| NCT06081673 | Penpulimab | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT04944043 | TQ05105 Tablets (Rovadicitinib Tablets) | Phase 1 | Chronic Graft Versus Host Disease | Immunology | Dec 2026 |
| NCT06195228 | Catequentinib | Phase 4 | Advanced Thyroid Cancer Patients Who Received Target Therapy | Oncology | Dec 2026 |
| NCT07806292 | Catequentinib | Phase 2 | Unresectable Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT04136535 | Catequentinib | Phase 2 | NSCLC Stage IV | Oncology | Dec 2026 |
| NCT07025174 | Catequentinib | Phase 2 | Bile Duct Carcinoma | Oncology | Dec 2026 |
| NCT06739395 | Catequentinib | Phase 2 | Solid Tumor | Oncology | Dec 2026 |
| NCT06249750 | Catequentinib | Phase 2 | Metastatic Castration-resistant Prostate Cancer (CRPC) | Oncology | Dec 2026 |
| NCT06354530 | Catequentinib | Phase 2 | Neoadjuvant Therapy | Oncology | Dec 2026 |
| NCT06379087 | Catequentinib | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT06331169 | Catequentinib | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT06693726 | Angiotensin Ii | Phase 4 | Septic Shock | Other | Dec 2026 |
| NCT05535738 | Adalimumab | Phase 2 | Skin Inflammation | Immunology | Jan 2027 |
The 60 nearest readouts of 164 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.